The Phase II study follows Phase I data presented at ASCO's annual meeting, in which half of the patients responded to the cell therapy.

In the firm's most recent financial report, it said it had enough cash and cash equivalents to fund operations into Q3 2026.

At ASCO, researchers reported that more patients who switched to camizestrant at molecular progression had total ctDNA ...

Eli Lilly announced a deal to buy the Boston biotech Kelonia for up to $7 billion last month after early results made a ...

Adjuvant treatment with the drug reduced the risk of recurrence by 83 percent in patients with RET-positive tumors, data that ...

At a public hearing hosted by the FDA, stakeholders said the program needs clearer eligibility criteria and insight into how ...

Researchers are refining autologous tumor-infiltrating lymphocyte treatment while testing CAR T-cell therapies in new tumor ...

The draft guidance outlines how sponsors can use publicly available, internal company, and other existing knowledge as part ...

At ASCO, the company reported 9 partial responses during the dose-escalation phase of the study in neuroendocrine tumors.

The firm is exploring a path forward for its gene-editing drug for chronic granulomatous disease, after saying last year it ...

The firm's share price jumped 15 percent following the full readout of the Phase III trial, which showed efficacy in those ...

Analysis of samples from the NATALEE trial, presented at ASCO, revealed some response-linked gene-expression patterns, but ...